Lung Cancer News

Nearly all individuals who received chemotherapy for extensive-stage small cell lung cancer experienced a treatment-related myelosuppressive episode, results of a retrospective study published in Cancer Medicine showed.

Preparing for her 2023-2024 term as American Thoracic Society president, M. Patricia Rivera, MD, ATSF, will continue working closely with the ATS executive committee and board of directors to evolve the organization’s strategic framework.

WASHINGTON — A lung nodule detection program saw an increase in low-dose CT for Black and Hispanic individuals after addressing screening barriers, according to research presented at the American Thoracic Society International Conference.

Glasgow prognostic score appeared associated with survival among patients with small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide, according to study results.

A commonly asked questions sheet addressing needs related to comprehension of lung cancer screening results was positively received by patients and clinicians, according to study results published in CHEST.

A prediction model that incorporates both exhaled breath data from an electronic nose and basic demographics was able to identify lung cancer in a cohort of patients, according to study results published in CHEST.

First-line osimertinib plus chemotherapy extended PFS compared with osimertinib alone for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, topline results of the randomized phase 3 FLAURA2 trial showed.

Lung nodule evaluations are crucial when working proactively against lung cancer, but some patients face disparities in managing them, according to a research statement published in American Journal of Respiratory and Critical Care.

Cancer death rates decreased overall across congressional districts in the United States over the past 25 years, according to a study published in Cancer.

The addition of cemiplimab to chemotherapy significantly improved pain symptoms and delayed time to definitive clinically meaningful deterioration of disease symptoms and functions among patients with advanced non-small cell lung cancer.